Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation

Blood

Volumn 127, Issue 4, 2016, Pages 449-457

  Yeomans, Alison ^a   Thirdborough, Stephen M ^a   Valle Argos, Beatriz ^a   Linley, Adam ^a   Krysov, Sergey ^a   Hidalgo, Marina Sanchez ^a   Leonard, Elodie ^a   Ishfaq, Muhammad ^a   Wagner, Simon D ^b   Willis, Anne E ^c   Steele, Andrew J ^a   Stevenson, Freda K ^a   Forconi, Francesco ^a,d   Coldwell, Mark J ^e   Packham, Graham ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c MRC TOXICOLOGY UNIT   (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE INHIBITOR; IBRUTINIB; IMMUNOGLOBULIN M ANTIBODY; INITIATION FACTOR 4A; INITIATION FACTOR 4G; MESSENGER RNA; MYC PROTEIN; ONCOPROTEIN; TAMATINIB; UNCLASSIFIED DRUG; AGAMMAGLOBULINAEMIA TYROSINE KINASE; ANTI-IGM; ANTIIDIOTYPIC ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN KINASE INHIBITOR; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; SIGNAL PEPTIDE;

ARTICLE; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CELL STIMULATION; CHRONIC LYMPHATIC LEUKEMIA; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RNA TRANSLATION; SINGLE CELL ANALYSIS; UPREGULATION; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; PATHOLOGY; PROTEIN SYNTHESIS; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANTIBODIES, ANTI-IDIOTYPIC; B-LYMPHOCYTES; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROTEIN BIOSYNTHESIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; PYRAZOLES; PYRIMIDINES; RECEPTORS, ANTIGEN, B-CELL; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84958087920     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-07-660969     Document Type: Article

References (47)

1. Packham G, Krysov S, Allen A, et al. The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy. Haematologica. 2014;99(7):1138-1148.
2. Mockridge CI, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood. 2007;109(10):4424-4431.
3. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
4. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood. 2012;120(24):4684-4691.
5. Smith MR. Ibrutinib in B lymphoid malignancies. Expert Opin Pharmacother. 2015;16(12):1879-1887.
6. Schwanhäusser B, Busse D, Li N, et al. Global quantification of mammalian gene expression control. Nature. 2011;473(7347):337-342.
7. Li JJ, Bickel PJ, Biggin MD. System wide analyses have underestimated protein abundances and the importance of transcription in mammals. PeerJ. 2014;2:e270.
8. Landon AL, Muniandy PA, Shetty AC, et al. MNKs act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL. Nat Commun. 2014;5:5413.
9. Horvilleur E, Sbarrato T, Hill K, et al. A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma. Leukemia. 2014;28(5):1092-1102.
10. Willimott S, Beck D, Ahearne MJ, Adams VC, Wagner SD. Cap-translation inhibitor, 4EGI-1, restores sensitivity to ABT-737 apoptosis through cap-dependent and -independent mechanisms in chronic lymphocytic leukemia. Clin Cancer Res. 2013;19(12):3212-3223.
11. Vallat LD, Park Y, Li C, Gribben JG. Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells. Blood. 2007;109(9):3989-3997.
12. Perrot A, Pionneau C, Nadaud S, et al. A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia. Blood. 2011;118(4):e1-e15.
13. Ruggero D, Montanaro L, Ma L, et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med. 2004;10(5):484-486.
14. Pickering BM, Willis AE. The implications of structured 59 untranslated regions on translation and disease. Semin Cell Dev Biol. 2005;16(1):39-47.
15. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene. 2004;23(18):3189-3199.
16. Pelletier J, Graff J, Ruggero D, Sonenberg N. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res. 2015;75(2):250-263.
17. Krysov S, Dias S, Paterson A, et al. Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells. Blood. 2012;119(1):170-179.
18. Herishanu Y, Pérez-Galán P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563-574.
19. Hallek M, Cheson BD, Catovsky D, et al; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
20. Matutes E, Catovsky D. The value of scoring systems for the diagnosis of biphenotypic leukemia and mature B-cell disorders. Leuk Lymphoma. 1994;13(Suppl 1):11-14.
21. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 2003;101(3):1087-1093.
22. Coelho V, Krysov S, Steele A, et al. Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function. Blood. 2013;122(15):2664-2672.
23. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.
24. Supek F, Bošnjak M, Škunca N, Šmuc T. REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS One. 2011;6(7):e21800.
25. Calo E, Flynn RA, Martin L, Spitale RC, Chang HY, Wysocka J. RNA helicase DDX21 coordinates transcription and ribosomal RNA processing. Nature. 2015;518(7538):249-253.
26. Krysov S, Steele AJ, Coelho V, et al. Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK. Blood. 2014;124(20):3101-3109.
27. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287-6296.
28. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471-484.
29. Liu J, Xu Y, Stoleru D, Salic A. Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin. Proc Natl Acad Sci USA. 2012;109(2):413-418.
30. Longo PG, Laurenti L, Gobessi S, et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia. 2007;21(1):110-120.
31. Iho S, Yamamoto T, Takahashi T, Yamamoto S. Oligodeoxynucleotides containing palindrome sequences with internal 59-CpG-39 act directly on human NK and activated T cells to induce IFN-gamma production in vitro. J Immunol. 1999;163(7):3642-3652.
32. Yang HS, Knies JL, Stark C, Colburn NH. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene. 2003;22(24):3712-3720.
33. van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 2010;10(4):301-309.
34. Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res. 2008;68(13):5326-5334.
35. Schmidt EV. The role of c-myc in regulation of translation initiation. Oncogene. 2004;23(18):3217-3221.
36. Mraz M, Kipps TJ. MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54(8):1836-1839.
37. Bui TV, Mendell JT. Myc: Maestro of MicroRNAs. Genes Cancer. 2010;1(6):568-575.
38. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539-2549.
39. Gao W, Wang M, Wang L, et al. Selective antitumor activity of ibrutinib in EGFR-mutant nonsmall cell lung cancer cells. J Natl Cancer Inst. 2014;106(9):dju204.
40. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88-94.
41. de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119(11):2590-2594.
42. Herman SE, Mustafa RZ, Jones J, Wong DH, Farooqui M, Wiestner A. Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo. Clin Cancer Res. 2015;21(20):4642-4651.
43. Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182-1189.
44. Steinhardt JJ, Peroutka RJ, Mazan-Mamczarz K, et al. Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase. Blood. 2014;124(25):3758-3767.
45. Chen R, Guo L, Chen Y, Jiang Y, Wierda WG, Plunkett W. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood. 2011;117(1):156-164.
46. Lucas DM, Edwards RB, Lozanski G, et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood. 2009;113(19):4656-4666.
47. Wiegering A, Uthe FW, Jamieson T, et al. Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer. Cancer Discov. 2015;5(7):768-781.